Saturday 17 October 2026 Export DYN’s income statement to Excel — free account

Dyne Therapeutics, Inc.

In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.25 1.04 −6.80%

Follow DYN

Alert me

Market cap: $2.9B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.31

Total sells 168.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	3	—	2	2	—	—	—	1
Sell	—	3	—	—	5	7	5	8	2	5	3	—

Insider Ownership 7.33%

Capital & Financial Ratios $m

Market Cap 2,860.00

Revenue —

Net Income (519.40)

Free Cash Flow (480.43)

Net Debt (685.00)

Current Ratio 12.02

Debt/Equity 0.30

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.36

Past 5Y EPS Growth —

This Y EPS Growth (4.49%)

Next Y EPS Growth 7.67%

Next Y revenue growth —

Next 5Y EPS Growth 10.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 67.81%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	123	642	1,111	898
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	129	659	1,127	938

	2023	2024	2025	Q'26
Payables	23	7	8	12
ST’ Debt	—	—	—	14
Other	—	—	—	—
	51	42	51	78

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	23.21%	56.76%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(145)	(130)	—	—	—
’25	(106)	(95)	(91)	(112)	(403)
’24	(79)	(55)	(75)	(84)	(292)
’23	(47)	(56)	(51)	(35)	(188)
’22	(51)	(31)	(43)	(29)	(154)
’21	(18)	(46)	(27)	(28)	(120)
’20	(7)	(7)	(12)	(20)	(47)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(145)	(132)	—	—	—
’25	(107)	(95)	(91)	(112)	(405)
’24	(79)	(56)	(75)	(85)	(295)
’23	(47)	(56)	(51)	(35)	(189)
’22	(52)	(31)	(44)	(30)	(157)
’21	(18)	(47)	(28)	(30)	(123)
’20	(7)	(7)	(12)	(21)	(48)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.73)	(1.08)	—	—	—
’25	(1.05)	(0.97)	(0.76)	(0.76)	(3.47)
’24	(0.81)	(0.70)	(0.96)	(0.88)	(3.37)
’23	(0.78)	(1.08)	(0.99)	(1.09)	(3.95)
’22	(0.69)	(1.01)	(0.80)	(0.74)	(3.23)
’21	(0.50)	(0.58)	(0.83)	(1.00)	(2.93)
’20	(0.90)	(3.31)	(2.01)	(0.64)	(4.13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	15.60	11.57	4.30	6.40	12.33	6.36	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	27.11	32.32	15.63	15.60	47.45	26.22
People
People	Employees	—	—	—	—	47	95	123	141	191	258
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(5)	(15)	(59)	(149)	(168)	(236)	(317)	(446)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(5)	(15)	(59)	(149)	(168)	(236)	(317)	(446)
	Depreciation	—	—	0	0	1	4	3	1	(2)	0
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(0.11)	(6.08)	(4.13)	(2.93)	(3.23)	(3.95)	(3.37)	(3.47)
	Cash flow	—	—	(0.09)	(4.84)	(3.23)	(2.35)	(2.96)	(3.15)	(3.11)	(3.14)
	Capex	—	—	0.00	(0.67)	(0.08)	(0.07)	(0.06)	(0.01)	(0.03)	(0.01)
	Free cash flow	—	—	(0.09)	(5.52)	(3.31)	(2.42)	(3.02)	(3.16)	(3.13)	(3.15)
	Book value	—	—	0.09	5.75	23.78	7.23	4.86	1.53	6.69	7.57
	Shares, m	—	—	45	2	14	51	52	60	94	128
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(4)	(12)	(47)	(120)	(154)	(188)	(292)	(403)
	Capex	—	—	0	(2)	(1)	(4)	(3)	(1)	(2)	(2)
	Free cash flow	—	—	(4)	(13)	(48)	(123)	(157)	(189)	(295)	(405)
Balance, $m
Balance, $m	Working capital	—	—	7	12	338	354	238	78	617	1,076
	Total debt	—	—	3	—	—	29	26	—	—	149
	Net debt	—	—	(5)	(15)	(345)	(348)	(230)	(123)	(642)	(962)
	Shareholders’ equity	—	—	4	14	342	368	252	91	630	972
Returns, %
Returns, %	ROA	—	—	(116.38)	(120.30)	(32.15)	(38.33)	(45.93)	(100.10)	(74.14)	(47.52)
	ROIC	—	—	0.00	0.00	0.00	(460.33)	(480.77)	0.00	0.00	(2,790.00)
	ROE	—	—	52.66	162.64	(36.13)	(42.02)	(54.18)	(137.31)	(88.03)	(55.71)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
RCUS Arcus Biosciences, Inc.	$2.9B	— (loss-making)	— (loss-making)	−74.38% (below 0%: shrinking)	n/m	+10.53% (above 0%: growing)	100.00%	(234.15%)	Compare
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%	Compare
BEAM Beam Therapeutics Inc.	$2.6B	— (loss-making)	— (loss-making)	−94.21% (below 0%: shrinking)	n/m	+13.92% (above 0%: growing)	100.00%	(25,827.14%)	Compare
Median of peers	$2.8B	—	—	−38.85%	—	+0.20%	96.16%	(35.97%)

All 614 Biotechnology stocks →

Dyne Therapeutics, Inc. (DYN) key facts

Dyne Therapeutics, Inc. (DYN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DYN traded at $14.25, a market capitalization of $2.9 billion.
Return on equity was −55.7% and debt-to-equity 0.30.

Source: company filings (standardised) and stockrow calculations.